GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Capex-to-Operating-Income

Kazia Therapeutics (Kazia Therapeutics) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Kazia Therapeutics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Kazia Therapeutics's Capital Expenditure for the six months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the six months ended in Dec. 2023 was $-5.95 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Kazia Therapeutics Capex-to-Operating-Income Historical Data

The historical data trend for Kazia Therapeutics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Capex-to-Operating-Income Chart

Kazia Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kazia Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kazia Therapeutics's Capex-to-Operating-Income

For the Biotechnology subindustry, Kazia Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kazia Therapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's Capex-to-Operating-Income falls into.



Kazia Therapeutics Capex-to-Operating-Income Calculation

Kazia Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -16.205
=N/A

Kazia Therapeutics's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -5.946
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kazia Therapeutics  (NAS:KZIA) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Kazia Therapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Kazia Therapeutics (Kazia Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
Executives
Josiah T Austin director, 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204